Rheumatologic aspects of pediatric cystic fibrosis patients treated with fluoroquinolones

Pediatric Infectious Disease Journal

Volumn 16, Issue 1, 1997, Pages 118-126

  Warren, Robert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

arthropathy; Ciprofloxacin; fluoroquinolones; joint toxicity

Indexed keywords

CIPROFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHROPATHY; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; JOINT INJURY; META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS; ARTHRALGIA; ARTHRITIS; CHILD; CIPROFLOXACIN; CYSTIC FIBROSIS; HUMANS;

EID: 0031051727     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199701000-00034     Document Type: Conference Paper

References (34)

1. Christ W, Lehnert T, Ulbrich B. Specific toxicologic aspects of the quinolones. Rev Infect Dis 1988;10:S141-6.
2. Schaad UB. Role of the new quinolones in pediatric practice. Pediatr Infect Dis J 1992;11:1043-6.
3. Mayer DG. Overview of toxicological studies. Drugs 1987; 34(Suppl 1):150-3.
4. Ingham B, Brentnall DW, Dale EA, McFadzean JA. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone 3-carboxylic acids. Toxicol Lett 1977;1:21-6.
5. Schlueter G. Toxicology of ciprofloxacin. In: First International Ciprofloxacin Workshop: Current Clinical Practice Series. Amsterdam: Excerpta Medica, 1986;34:61-70.
6. Tatsumi H, Senda H, Yatera S, Takemoto Y, Yamayoshi M, Ohnishi K. Toxicological studies on pipemidic acid. V. Effects on diarthrodial joints of experimental animals. J Toxicol Sci 1978;3:357-67.
7. Schlueter G. Ciprofloxacin: toxicologic evaluation of additional safety data. Am J Med 1989;87(Suppl 5A):37-9.
8. Hoffmann K, Desprechins B. Joint lesions induced by quinolones: differences between clinical, MRI and post-mortem findings. In: Proceedings of the Third International Symposium on New Quinolones. Eur J Clin Microbiol Infect Dis 1991;Special issue:393.
9. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, De La Iglesia FA. Juvenile canine drug induced arthropathy: clinicopathological studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87.
10. Stahlmann R, Merker HJ, Hinz N. Ofloxacin in juvenile non-human primates and rats: arthropathia and drug plasma concentrations. Arch Toxicol 1990;64:193-204.
11. Schmidt M, Hoffman K. The use of quinolones in children: toxicological aspects. Adv Antimicrob Antineoplast Chemother 1992;11:S251-5.
12. Ribard P, Kahn MF. Rheumatological side-effects of quinolones. Baillieres Clin Rheumatol 1991;5:175-91.
13. Amacher DE, Schomaker SJ, Gontz TD, McGuirk PR. Proteoglycan and procollagen synthesis in rat embryo limb bud cultures treated with quinolone antibacterial. Altern Methods Toxicol 1989;7:307-12.
14. Brand HS, van Kampen GP, van der Korst JK. Effect of nalidixic acid, pipemidic acid and cinoxacin on chondrocyte metabolism in explants of articular cartilage. Clin Exp Rheumatol 1990;8:393-5.
15. Kato M, Onodera T. Effect of ofloxacin on the uptake of (3H) thymidine by articular cartilage cells in the rat. Toxicol Lett 1988;44:131-42.
16. Bendele AM, Hulman JF, Harvey AK, Hrubey PS, Chandrasekhar S. Passive role of articular chondrocytes in quinolone-induced arthropathy in guinea pigs. Toxicol Pathol 1990;18:304-12.
17. Bailey RR, Natale R, Linton AL. Nalidixic acid arthralgia. Can Med Assoc J 1972;107:604-7.
18. Adam D. Use of quinolones in pediatric patients. Rev Infect Dis 1989;11:S1113-6.
19. Schaad UB, Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection 1987;15:165-8.
20. Rubio TT. Ciprofloxacin in the treatment of Pseudomonas infection in children with cystic fibrosis. Diagn Microbiol Infect Dis 1990;13:153-5.
21. Schaad UB, Sander E, Wedgwood J, Schaffner T. Morphological studies for skeletal toxicity after prolonged ciprofloxacin therapy in two juvenile cystic fibrosis patients. Pediatr Infect Dis J 1992;11:1047-9.
22. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in pediatric patients with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991;10:723-9.
23. Alfaham M, Holt M, Goodchild M. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br Med J 1987;295: 699.
24. Black A, Redmond AOB, Steen HJ, Oborska IT. Tolerance and safety of ciprofloxacin in paediatric patients. J Antimicrob Chemother 1990;26(Suppl F):25-9.
25. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Quinolones in clinical use: safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use - emphasis on joint evaluation. Infection 1991;19: 289-96.
26. Kuhn RJ, Palmejar A, Kanga JF. Tolerability of ciprofloxacin in pediatric patients with cystic fibrosis. Adv Antimicrob Antineoplast Chemother 1992;11:S269-71.
27. Orenstein DM, Pattishal EN, Noyea BE, Kurland G, Hartigan ER, Yu VL. Safety of ciprofloxacin in children with cystic fibrosis. Clin Pediatr 1993;32:504-6.
28. Dixey J, Redington AN, Butler RC, et al. The arthropathy of cystic fibrosis. Ann Rheum Dis 1988;47:218-23.
29. Rush PJ, Shore A, Coblentz C, Wilmot D, Corey M, Levinson H. The musculoskeletal manifestations of cystic fibrosis. Semin Arthritis Rheum 1986;15:213-25.
30. Artheya BH, Boms P, Rosenlund ML. Cystic fibrosis and hypertrophic osteoarthropathy in children. Am J Dis Child 1975;129:634-7.
31. Portuiset E, Menkes CJ, Lenoir G, Jehanne M, Douchain F, Guillot M. Cystic fibrosis arthritis: a report of five cases. Br J Rheumatol 1992;31:535-8.
32. Newman AJ, Ansell BM. Episodic arthritis in children with cystic fibrosis. J Pediatr 1979;94:594-6.
33. Phillips B, David T. Pathogenesis and management of arthropathy in cystic fibrosis. J R Soc Med 1986;79(Suppl 12):44-60.
34. Church DA, Kanga JG, Kuhn RJ, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatr Infect Dis J 1997;16:97-105.